sotatercept (Winrevair)
Jump to navigation
Jump to search
Indications
- reduces pulmonary vascular resistance in patients receiving therapy for pulmonary arterial hypertension (FDA-approved)
Dosage
- 0.3-0.7 mg/kg of body weight every 3 weeks SQ
Adverse effects
- thrombocytopenia
- erythrocytosis
- cardiac arrest (1 death in 24 week trial of 106 patients)[1]
Mechanism of action
- binds activins & growth differentiation factors
- attempts to restore balance between growth-promoting & growth-inhibiting signaling pathways
- sotatercept decreases N-terminal pro-B-type natriuretic peptide levels
More general terms
References
- ↑ 1.0 1.1 Humbert M, McLaughlin V, Gibbs JSR et al Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384:1204-1215. April 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33789009 https://www.nejm.org/doi/full/10.1056/NEJMoa2024277
- ↑ Lou N Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension. Biologic should arrive on pharmacy shelves before May. MedPage Today March 27, 2024 https://www.medpagetoday.com/cardiology/hypertension/109372
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATIO Winrevair<TM> sotatercept-csrk for injection, for subcutaneous use https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf